Search
for

    Learn

    5 / 801 results

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Adenosine

      nucleoside used for hair regrowth stimulant properties

      learn Alfatradiol

      a synthetic estrogen used topically as an anti-androgen

      learn Dutasteride

      Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Why balding gets worse in every generation?

      in Chat  81 upvotes 1 year ago
      Balding seems to worsen with each generation, possibly due to stress, diet, and environmental factors. The user started treatments like Minoxidil and finasteride.

      community DUPA / APHK discussion ( Diffuse unpatterned alopecia / Acquired Progressive Hair Kinkering )

      in Treatment  4 upvotes 6 years ago
      The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

      community Naturally high T (1,100+) causing diffuse thinning while on Dut

      in Chat  22 upvotes 2 months ago
      A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.